Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- The AI CEO™ Launches Next-Gen Sales Assistant for Equipment Finance Professionals
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.
SAN DIEGO - Michimich -- About John Burd, PhD:
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on Michimich.com
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
4930 Bradshaw Court, San Diego, CA 92130
More on Michimich.com
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on Michimich.com
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Rocket Companies Completes Acquisition of Redfin
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
4930 Bradshaw Court, San Diego, CA 92130
More on Michimich.com
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- NEW CHILDREN'S BOOK RELEASE: "Mommy, Where Is My Daddy?" by Tracy L. Gray
- UNIVERSAL MUSIC GROUP AND THE UCLA HERB ALPERT SCHOOL OF MUSIC ESTABLISH THE BERRY GORDY MUSIC INDUSTRY SCHOLARSHIP TO HONOR THE LEGACY OF A MUSIC PIONEER
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Source: Beneficience.com Legacy PR
0 Comments
Latest on Michimich.com
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- PrideStaff Detroit (West) Named One of Detroit's Top Staffing Agencies for Second Year by ThreeBestRated®
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- The AI CEO™ Launches Next-Gen Sales Assistant for Equipment Finance Professionals
- PGA Tour's Rocket Mortgage Classic: Detroit Readies for a Championship Clash
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion